While droves of patients experiencing obesity have turned to Novo Nordisk’s Ozempic for treatment, the drug Mounjaro from its competitor Eli Lilly is closely trailing its success, according to an April 3 report from The Wall Street Journal.
Read the full post on Becker's Hospital Review - Healthcare News
